The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Researchers found that recurrences were rare for patients receiving adjuvant erlotinib.
Researchers reported that ablation of pulmonary malignant tumors may be a safe treatment option in select patients.
Combination therapy showed activity in epidermal growth factor receptor-mutated, mesenchymal-epithelial transition factor-dysregulated non-small-cell lung cancer.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer CentersNovember 15, 2018
Better collaboration between community and academic cancer centers could benefit patients.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.
This trial in NSCLC was terminated early when the investigational drug become unavailable following the dissolution of a partnership between the drug's codevelopers.
Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.
Scientific models project a continued decrease in lung cancer mortality.
Management strategies were identified for lung cancer patients who experienced hyperprogressive disease during treatment with nivolumab.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
The 2 most common resistance mechanisms were MET amplification, EGFR C797S mutation.
Brigatinib significantly delayed time to intracranial progression and prolonged PFS compared with crizotinib in patients with ALK+ NSCLC with intracranial metastases.
Approximately one-third of patients with NSCLC with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLCOctober 17, 2018
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical BenefitOctober 05, 2018
The only single-arm cancer trials to show a substantial benefit were those for osimertinib for T790-mutated NSCLC and crizotinib for ALK-rearranged NSCLC.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Many immunotherapy-based combinations are being studied in NSCLC, with TMB emerging as a potential predictive biomarker.
CT lung cancer screening substantially reduces lung cancer deaths among asymptomatic patients at high risk for developing lung cancer.
Tislelizumab, an anti-PD-1 antibody, demonstrated antitumor activity in phase 1 and phase 2 trials of Chinese patients with advanced lung cancers.
Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.
In 18% of advanced lung adenocarcinoma cases, the assay identified FDA-approved or NCCN guideline-recommended targeted therapies for patients.
Interim data from a phase 2 trial suggests that MET inhibitor tepotinib has antitumor activity and a tolerable safety profile in advanced MET exon 14 skipping mutated NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?